Mechanism and New Findings in Brugada Syndrome

Wataru Shimizu, MD; Takeshi Aiba, MD; Shiro Kamakura, MD

Brugada syndrome is a clinical entity characterized by coved-type ST-segment elevation in the right precordial electrocardiographic leads (V1–3) and an episode of ventricular fibrillation in the absence of structural heart disease. Although a number of clinical and experimental reports have elucidated the electrocardiographic, electrophysiologic, cellular, and molecular aspects, several problems remain unsolved. Recently developed high-resolution optical mapping techniques in arterially-perfused wedge preparations enable recording of transmembrane action potentials from 256 sites simultaneously at the epicardial surface, thus providing further advances in the understanding of the cellular mechanism of the specific ST-segment elevation and subsequent ventricular arrhythmias. In this review article, new findings relating to several unresolved problems such as gender difference (male predominance) and ethnic difference (higher incidence in Asian population) are also presented. (Circ J 2007; Suppl A: A-32–A-39)

Key Words: Brugada syndrome; Ethnicity; Gender; Genetics; Mutation; Polymorphism; ST-segment; Ventricular fibrillation

Brugada syndrome (BS) is characterized by coved-type ST-segment elevation in the right precordial electrocardiography (ECG) leads (V1–3) and an episode of ventricular fibrillation (VF) in the absence of acute ischemia, electrolyte abnormalities or structural heart disease.5–8 A type-1 ST-segment elevation, which is defined as a coved ST-segment elevation of ≥0.2 mV at the J point with or without a terminal negative T wave, is required to diagnose BS, regardless of the absence or presence of sodium-channel blockers (Figs 1A,B).9 A type-1 ST-segment elevation recorded only in the higher V1–2 leads (ie, 3rd and 2nd intercostal spaces) has been suggested to show similar prognostic value for subsequent cardiac events as that recorded in the standard V1–2 leads (Fig 1C).7,9,10 A type-2 saddle-back ST-segment elevation alone is not diagnostic for BS (Fig 1B). The prevalence of this syndrome is estimated to be 5 per 10,000 inhabitants, and is one of the important causes of sudden cardiac death of middle-aged males in Asian countries particularly.11,12 BS usually manifests during adulthood, with a mean age of sudden death of 41±15 years, and child cases are rare.7 A family history of unexplained sudden death is present in approximately 20–40% of the population in Western countries, and less (15–20%) in Japan.4,7,13,14 A significant male predominance in BS has long been reported, and more than 80% of patients in Western countries and more than 90% of patients in Asian countries affected with BS are men.15 Since Brugada and Brugada described 8 patients with a history of aborted sudden cardiac death caused by VF as a distinct clinical entity in 1992,1 a number of clinical and experimental reports from around the world have demonstrated the clinical, electrocardiographic, electrophysiologic, cellular, ionic, genetic and molecular features of BS.2–14 However, several problems remain unsolved, such as genetic heterogeneity, late onset of first cardiac events, and gender and ethnic differences.16 In this review article, we present our recent data relating to the cellular and molecular mechanism of BS, the late onset of its clinical manifestation, male predominance, and higher incidence in Asian populations.

Genetic and Molecular Aspects

Advances in molecular genetics in the past decade have established a link between several inherited cardiac arrhythmias, including BS and long QT syndrome, and mutations in genes encoding ion channels, membrane components or receptors.16 In 1998, the first mutation linked to BS was identified by Chen et al in SCN5A,17 the gene encoding the Î subunit of the sodium channel. Thereafter, a large family of BS was reported to link to a second locus on chromosome 3, which is close to but different from the SCN5A locus;18 however, specific gene or genes other than SCN5A have not yet been identified on chromosome 3. SCN5A mutations are reported to account for 18–30% of clinically diagnosed BS patients at present.19 Antzelevitch et al have recently reported that 3 probands associated with a BS-like ST-segment elevation and a short QT interval were linked to mutations in CACNA1C (A39V and G490R) or CACNB2 (S481L), the gene encoding the Î1 or Î2b subunit of the L-type calcium channel, respectively.20 Their genetic and heterologous expression studies revealed loss of function of the L-type calcium channel current (Ica-L). However, approximately two-thirds of BS patients have not been yet genotyped, suggesting the presence of genetic heterogeneity.21 Other candidate genes for the Brugada phenotype include those encoding the transient outward current (Ito) and the delayed rectifier potassium current (Ikr) or those coding the adrenergic receptors, cholinergic receptors, ion-channel-interacting protein, promoters, transcriptional factors, neurotransmitters, or transporters.7,8

Among the approximately 100 mutations in SCN5A linked to BS, some of them have been studied in expression systems, and have been shown to result in loss of function of the sodium channel current (Isn) by several mechanisms.22
These functional effects include: (1) lack of expression of the sodium channel; (2) a shift in the voltage-dependence and time-dependence of \( \text{INa} \) activation, inactivation or reactivation; (3) entry of the sodium channel into an intermediate state of inactivation from which it recovers more slowly; (4) accelerated inactivation of the sodium channel; and (5) a trafficking defect. Some common \( \text{SCN5A} \) polymorphisms are reported to modulate the functional consequences of primary \( \text{SCN5A} \) mutations. Baroudi et al first suggested that the interaction of \( \text{SCN5A} \) polymorphisms and \( \text{SCN5A} \) mutations may affect the consequence of the functional effects. They reported that a common polymorphism (R1232W) of \( \text{SCN5A} \) affected protein trafficking when it was co-expressed with a T1620M mutation, although the T1620M mutation alone produced only gating abnormalities in the \( \text{INa} \).21 On the other hand, another common polymorphism (H558R) of \( \text{SCN5A} \) was reported by Ye et al to rescue normal trafficking and normal \( \text{INa} \) for the M1766L mutant protein.22 These effects of common \( \text{SCN5A} \) polymorphisms on modifying the functional consequence of \( \text{SCN5A} \) mutations may make the clinical phenotype more complex.

### Cellular Mechanism of Brugada Phenotype

The \( \text{Ito} \)-mediated phase 1 notch of the action potential (AP) has been reported to be larger in the epicardium than in the endocardium in many species, including humans.23 Because the maintenance of the AP dome is determined by the fine balance of currents active at the end of phase 1 of the AP (principally \( \text{Ito} \) and \( \text{ICa-L} \)), any interventions that cause a net outward shift in the current active at the end of phase 1 can increase the magnitude of the AP notch, leading to loss of the AP dome (all-or-none repolarization) in the epicardium, but not in the endocardium, contributing to a significant voltage gradient across the ventricular wall during ventricular activation.23 The heterogeneous loss of the AP dome in the epicardium has been shown to produce premature beats via a mechanism of phase 2 reentry in experimental studies using isolated sheets of canine right ventricle.24 Therefore, these mechanism of all-or-none repolarization in the epicardial cells and phase 2 reentry-induced premature beat between the adjacent epicardial cells were expected to be responsible for the clinical phenotype in BS.

In the late 1990s, Antzelevitch’s group developed an experimental model of BS using arterially perfused canine right ventricular (RV) wedge preparations, in which transmembrane APs and pseudo-ECGs were simultaneously recorded. These experimental studies have provided significant insights of the cellular mechanism of the Brugada phenotype, ST-segment elevation and subsequent VF.25,26 The \( \text{Ito} \)-mediated AP notch and the loss of the AP dome in the epicardial cells, but not in the endocardial cells, of the right ventricle gives rise to a transmural voltage gradient, producing ST-segment elevation in the ECG in the wedge preparations. Fig 2 shows transmembrane APs simultaneously recorded from 2 epicardial (Epi) and 1 endocardial sites, together with a transmural ECG in a Brugada model using the RV wedge preparation. Under control conditions, a small J wave coincides with the small notch observed in the epicardial cells, but not in the endocardial cells (Fig 2A). Combined administration of terfenadine (\( \text{ICa-L} \) block) and pilsicainide (\( \text{INa} \) block) produces a loss of the AP dome in
Epi 1, but not in Epi 2, resulting in a marked epicardial dispersion of repolarization (EDR), and a coved-type ST segment elevation and negative T wave in the ECG (Fig 2B). A selective Ito blocker, 4-aminopyridine, restores the AP dome, decreases the phase 1 AP notch, and normalizes the ST-segment elevation (Fig 2C). Fig 2D shows non-sustained polymorphic ventricular tachycardia (VT) via phase 2 reentry induced in a Brugada model using the wedge preparation. In the setting of remarkable coved type ST-segment elevation with combined administration of terfenadine and pilsicainide, heterogeneous loss of the AP dome (coexistence of loss of dome regions and restored dome regions) in the epicardium creates a marked EDR, giving rise to premature beats caused by phase 2 reentry, which precipitates non-sustained polymorphic VT.

**Optical Mapping Study**

The AP data in the Brugada model using arterially perfused canine RV wedge preparations strongly supported the hypothesis that episodes of VF in BS are triggered by premature beats between the adjacent epicardial cells via the mechanism of phase 2 reentry. However, the precise mechanism of the initial premature beats and the maintenance of non-sustained polymorphic VT or VF remain unsolved, because the number of AP recording sites available for floating microelectrodes is small in the wedge preparations. To overcome this limitation, we recently developed high-resolution (256×256) optical mapping techniques that allowed us to record transmembrane APs from 256 sites simultaneously at the epicardial or endocardial surface of the wedge preparations (Figs 3–5). Fig 3 shows the mechanism of phase 2 reentry-induced premature beats (P2-extrasystoles) under Brugada-ECG conditions. A steep repolarization gradient between the loss of dome region and the restored dome region in the epicardium, but not in the endocardium, develops the initial P2R-extrasystole. We then recorded spontaneous episodes of P2R-extrasystoles and subsequent non-sustained polymorphic VT or VF under these conditions, and analyzed the epicardial AP duration (APD) and conduction velocity (Figs 4, 5). Once again, most of the P2R-extrasystoles originated from the area showing the steepest (maximum) gradient of repolarization (GRmax) between the loss of dome site and the restored dome site in the epicardium (Figs 4C, 5C, arrows), leading to non-sustained polymorphic VT or VF. These data also indicate that a steep repolarization gradient between the loss of dome region and the restored dome region in the epicardium is essential to produce the P2R-extrasystoles that precipitate polymorphic VT or VF. On the other hand, the epicardial GRmax does not differ between episodes of polymorphic VT and those of VF. Figs 4D, E and 5D, E show the mechanism underlying the difference between polymorphic VT and VF. Just before inducing the episodes of polymorphic VT or VF, the epicardial depolarization map paced from the endocardium at the basic cycle length of 2,000 ms shows a remarkable conduction delay in the episode of VF (Fig 5D) compared with that of polymorphic VT (Fig 4D). The conduction parameters, such as QRS duration and interval between the stimulus and the earliest epicardial activation, are significantly longer in the episodes of VF than in those of polymorphic VT. Figs 4A, B
represents a phase map and the optical APs during the P2R-induced polymorphic VT, showing that reentry is initiated from the epicardial GRmax area and rotates mainly in the epicardium without wave-break. In contrast, Figs 5A,B represents these during P2R-induced VF, showing that the development of the initial P2R is similar to that of polymorphic VT, but that the first P2R-wave is broken up into multiple wavelets, resulting in degeneration of VF into VT. The phase singularity points during the first P2R-wave almost coincide with the sites of delayed conduction (Fig 5D). Wave-break during the first P2R-extrasystole produces multiple wavelets in the episodes of VF, whereas no wave-break or wave-break followed by wave collision and termination occurs in the episodes of polymorphic VT. Figs 4E and 5E are histograms of the epicardial APD measured at 50% (APD50) during the first P2R-wave. There is a large variety of APD50 in the epicardium during the first P2R-wave in the episodes of VT, whereas only slight variety in the APD50 is observed in the episodes of polymorphic VT. These data suggest that both conduction delay and dispersion of repolarization play significant roles in the perpetuation of VF episodes.

Late Onset of Clinical Manifestation

Because BS is a primary electrical disease, and at least one-third of the patients have mutations in ion channel genes (SCN5A, CACNA1C, CACNB2), clinical manifestation during childhood would be expected. However, BS usually manifests in middle age, at 40–50 years of age. Frustaci et al recently reported a significant myocytes apoptosis in both the right and left ventricular myocardium in a histological study of BS patients with SCN5A mutations, and suggested that abnormal function of the sodium channels may lead to a sufficient degree of cellular damage, attributing to the arrhythmic event. We recently analyzed several ECG parameters recorded during long-term follow-up of BS patients with and without the SCN5A mutation. In both patient groups, the depolarization parameters, including P wave, QRS, S wave duration and PQ interval, increased with age, especially in patients with the SCN5A mutation. Taken together with the experimental data, the findings suggest that depolarization abnormalities (conduction slowing) are required for the maintenance of VF in BS, although the initiating premature beats are caused by a phase 2 re-entry mechanism.
Male Predominance

Because all mutations so far identified in SCN5A display an autosomal dominant mode of transmission in BS, males and females would be expected to inherit the defective gene equally. However, an apparent male predominance is observed in patients with BS. Di Diego et al suggested the cellular basis for male predominance in BS while using arterially-perfused canine RV wedge preparations. They reported that the I_to-mediated phase 1 AP notch in the RV epicardium was larger in male dogs than in female dogs was responsible for the male predominance in the Brugada phenotype. On the other hand, the male hormone, testosterone, has been reported to increase the outward potassium currents (the rapidly [IKr] and the slowly [IKs] activating component of IK, and the inward rectifier potassium current [IK1]) or decrease the inward currents (ICa-L). Therefore, testosterone would be expected to accentuate the Brugada phenotype. Clinically, Matsuo et al report 2 cases of asymptomatic BS in which typical coved ST-segment elevation disappeared following orchiectomy as therapy for prostate cancer supporting the expectation for testosterone. Moreover, testosterone is also known to decrease visceral fat and patients with BS are thinner than the normal population. On the basis of these clinical and experimental findings, we directly measured the testosterone level in male patients with BS and compared them with age-matched normal males. The testosterone level was significantly higher and body mass index (BMI) significantly lower in the Brugada males than in the controls after adjusting for several confounding variables including testosterone level or BMI (eg, age, exercise, stress, smoking, and medication). Interestingly, testosterone level was inversely correlated with BMI in both Brugada and control males even after adjusting for confounding variables, suggesting that Brugada males have a higher testosterone level associated with lower visceral fat (Fig 6). Moreover, conditional logistic regression model analysis showed that both higher testosterone level and lower BMI independently increase the risk of BS. These data suggest that the male predominance in the Brugada phenotype is at least in part related to testosterone, which is present only in males.

Higher Incidence in Asian Population

The incidence of BS is higher in Asian countries, including Thailand and Japan, than in Western countries. It has been reported that common polymorphisms might modulate the activity of the primary disease-causing mutation or influence susceptibility to arrhythmia, even in the general population. The common polymorphisms may attribute to ethnic differences in the clinical phenotype in inherited cardiac arrhythmias, including BS, because some common polymorphisms are ethnically dependent. Pfeuffer et al reported that polymorphisms in the SCN5A promoter were associated with a widening of QRS duration in a cen-
We recently identified a haplotype variant consisting of 6 individual DNA polymorphisms in near-complete linkage disequilibrium within the proximal promoter region of \textit{SCN5A} in Asians only (an allele frequency of 22%), not in Caucasian or African-Americans (Fig 7). Luciferase reporter activity of this variant haplotype, designated Haplotype B, in cardiomyocytes is reduced 62% compared with the wild-type, designated Haplotype A. To test the hypothesis that this \textit{SCN5A} promoter polymorphism may modulate variability in cardiac
conduction, the relationship between the SCN5A promoter haplotype and indices of conduction velocity (i.e., PR and QRS durations) was analyzed in a cohort of 71 Japanese BS subjects without SCN5A mutations and in 102 Japanese controls. In both groups, PR and QRS durations were significantly longer in Haplotype B individuals, with a gene–dose effect (Fig 8). Moreover, increases in both the PR and QRS duration with sodium channel blockers, which are known to be arrhythmogenic in BS, were genotype-dependent and a gene–dose effect was also observed. These data demonstrate that the Haplotype B within the SCN5A promoter region alone does not give rise to BS, but that it likely contributes to a higher incidence of BS in Asian population in combination with other yet unknown (genetic) factors.
Acknowledgments

Dr W Shimizu was supported by the Uehara Memorial Foundation, the Hoashia Research Foundation, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science and Technology Leading Project for Biosimulation, and Health Sciences Research Grants (H18-Research on Human Genome-002) from the Ministry of Health, Labour and Welfare, Japan.

References


